PATENT CLAIM ANALYSIS

Application Number: 15945011
Application Type: Utility
Filing Date: 2018-04
Publication Date: 2018-10
Patent Classification: ["424", "138100"]

Abstract:
The present invention relates to antibodies that are heterodimeric and bind human PD-L1 and human TIM-3, and may be useful for treating cancer alone and in combination with chemotherapy and other cancer therapeutics.

Claim (Index 12):
A pharmaceutical composition, comprising the antibody of  claim 3  and an acceptable carrier, diluent, or excipient.

Metadata:
- Claim Count in Document: 3.0
- Percentile: 91.0
- Lexical Diversity: 1.2069
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15239959', '15232026', '16064727', '15005042', '14709514']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7690676044101775
- 35 USC 102 Novelty (BERT): 0.5205797198565119
- Combined Prediction Score: 0.744218815954811
- Mean Citation Score: 328.78834399999994
- Max Citation Score: 344.3392
- Similarity Product: 312.9458112007141

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 0

Dataset: test